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Science, Shiga, JapanSelective targeting of drugs to tumor cells is a key goal in
oncology.Here,weperformedan in vivophagedisplay to identify
peptides that specifically target xenografted prostate cancer cells.
This yielded three peptide candidates, LN1 (C-TGTPARQ-C),
LN2 (C-KNSMFAT-C), and LN3 (C-TNKHSPK-C); each of
these peptides was synthesized and evaluated for binding
and biological activity. LN1 showed the highest avidity for
LNCaP prostate cancer cells in vitro and was thus administered
to tumor-bearing mice to evaluate in vivo binding. Strikingly,
LN1 specifically bound to the tumor tissue and exhibited very
low reactivity with normal liver and kidney tissues. To demon-
strate that LN1 could specifically deliver drugs to prostate cancer
tissue, a therapeutic peptide, LN1-KLA (C-TGTPARQ-C-
GGG-D[KLAKLAK]2), was prepared and used to treat LNCaP
cells in vitro and was also administered to tumor-bearing mice.
The therapeutic peptide significantly suppressed growth of the
cells both in vitro and in vivo. Our study shows that a selective
homing peptide strategy could facilitate cell-specific targeting
of therapeutics while avoiding adverse reactions in normal
tissues.Received 10 December 2018; accepted 10 January 2019;
https://doi.org/10.1016/j.omto.2019.01.001.
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Although several therapeutic options are available to treat localized
prostate cancer, metastatic disease is associated with a poor prog-
nosis in prostate cancer patients. Currently, androgen deprivation
therapy is the standard treatment for metastatic prostate cancer.1
Despite the initial favorable response, many patients die once castra-
tion-resistant disease emerges.2 The development of novel drugs,
such as abiraterone, enzalutamide, and cabazitaxel, has improved
survival to some extent.3–6 However, in many instances, treatment
has to be discontinued due to the appearance of systemic adverse
reactions. To overcome the limitations of these current therapies,
there is a pressing need for a treatment strategy that allows selective
targeting of cancer tissue while avoiding adverse effects on non-
target tissues.
Homing peptides capable of selectively delivering many kinds of mol-
ecules have been identified and hold great promise for the develop-
ment of less toxic therapeutic methods to treat several diseases.7–10138 Molecular Therapy: Oncolytics Vol. 12 March 2019 ª 2019 The Au
This is an open access article under the CC BY-NC-ND license (httpThese homing peptides usually consist of 3–12 amino acids with
exceptionally strong binding affinity and selectivity for their target
molecules.11,12 These peptides can be screened using phage display
technology, which is an efficient method for searching a peptide li-
brary in order to identify a sequence that specifically binds to a target
molecule.13,14 The method can be used both in vitro and in vivo;15,16
the latter approach allows the identification of homing peptides that
target the surface of cells in their physiological microenviron-
ment.12,16–21 Combining these homing peptides with an anticancer
agent promotes more effective tumor regression than use of the anti-
cancer agent alone.18 In addition, conjugation of these peptides to
pro-apoptotic peptide sequences can be used to selectively induce
cancer cell death.19
The existing in vivo phage display technology is problematic, as it
does not consistently identify peptides that discriminate disease tissue
from normal tissue.22,23We designed the current study to address this
issue. Specifically, we performed an initial phage display that identi-
fied peptides that did not bind to host tissues; this library subgroup
was then used to identify peptides that homed to prostate cancer cells.
Furthermore, in order to minimize toxicity to human normal tissues,
we performed phage display on a cynomolgus monkey in addition to
normal mice to collect phage populations that did not bind to non-
diseased organs. Our approach provides an advanced strategy to
isolate non-toxic homing peptides that specifically bind to cancer
cells.RESULTS
Identification of Prostate Cancer Homing Peptides Using In Vivo
Phage Display
To exclude phage binding to normal tissues, we used blood as the
source of peptides that did not bind to systemic organs. Threethor(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of the
Advanced Screening Procedure to Identify Homing
Peptides Targeting Prostate Cancer
Negative selection: an in vivo phage display was per-
formed to collect non-binding phages to normal tissues
in mice (upper) and a cynomolgus monkey (middle).
After negative selection, specific peptides homing to the
cancer cells were identified by in vivo phage display in
SCID mice bearing tumor xenografts (lower). TU, titer
unit.
www.moleculartherapy.orgrounds of in vivo phage display in mice and one round of in vivo
phage display in a cynomolgus monkey were performed to collect
this “negative” phage population (Figure 1). The DNA sequences
of the isolates were analyzed; this confirmed that phage diversity
was maintained (data not shown). A similar DNA analysis was
performed after completion of four rounds of in vivo phage
display in severe combined immunodeficient (SCID) mice with
prostate cancer tissue transplantation (Figure 1). Thirty-two
sequences, indicative of high-affinity binding peptides, were iden-
tified in this manner (Table 1). LN1 (C-TGTPARQ-C) and LN2
(C-KNSMFAT-C) peptides were the most frequent among the
32 candidate peptides and were found in 4 of 47 phage plaques
(frequency, 8.5%) (Table 1). LN3 (C-TNKHSPK-C) and LN4
(C-SPKNILH-C) peptides were the next most frequent and were
observed in 3 of 47 phage plaques (frequency, 6.4%) (Table 1).
Due to their occurrence at high frequency, LN1, LN2, and LN3Molecularwere selected as candidate prostate cancer
homing peptides for further experiments.
Binding Affinity of LN1, LN2, and LN3
Peptides to Cancer Cells
To examine differences in the binding affinity
of LN1, LN2, and LN3 peptides to cancer
cells, each peptide was synthesized and conju-
gated with biotin at the N terminus before
incubation with LNCaP cells for 24 h. Rhoda-
mine (tetramethylrhodamine isothiocyanate
[TRITC]) avidin D was applied and the bind-
ing ratio of LN1-LN3 peptides to LNCaP pros-
tate cancer cells was calculated (Figure 2).
Most of the cells were labeled with all three
peptides (Figure 2A), whereas the control pep-
tide (C-GPRTQTA-C, a scrambled sequence of
the LN1 peptide) showed negligible signal
(data not shown). The proportion of LN1 pep-
tide bound to tumor cells was 95.1% (Fig-
ure 2B). In contrast, the binding of LN2 and
LN3 peptides were 86.4% and 66.7%, respec-
tively (Figure 2B). Fluorescent immunostain-
ing also confirmed that LN1 bound the most
avidly to tumor cells (Figure 2C). We thus
conclude that the LN1 peptide is the mostoptimal homing peptide for specific binding to prostate cancer
tissue.
In Vivo Targeting of LN1, LN2, and LN3 Homing Peptides to
Prostate Cancer
LN1, LN2, and LN3 peptides were individually administered to SCID
mice harboring subcutaneous LNCaP transplants and 3,3-diamino-
benzidine (DAB) staining was performed to evaluate the extent of
binding to tumor tissues and other major organs with high blood
perfusion rates, such as liver and kidney. While LN1, LN2, and
LN3 peptides bound to tumor tissue, the control peptide showed
negligible binding (Figure 3). Strikingly, the LN1 and LN2 peptides
did not bind to the liver or kidney tissue (Figure 3). Although the pep-
tide showed a small but significant amount of binding to the kidney
tissue, it did not bind to the liver (Figure 3). On the other hand, the
control peptide bound to both liver and kidney tissue (Figure 3).Therapy: Oncolytics Vol. 12 March 2019 139
Table 1. Amino Acid Sequence and Phage Plaque Frequencies of Peptides
That Specifically Home on Prostate Cancer Cells

































Molecular Therapy: OncolyticsGiven the results of the in vitro and in vivo experiments, we selected
LN1 for further experiments to determine its potential utility for
treatment of prostate cancer.
LN1 Homing Peptides Localize to Prostate Cancer Cells In Vivo
We performed fluorescent staining to determine the localization
of LN1 in each tissue. The LN1 peptide displayed strong local-
ization to tumor tissue, whereas the control peptide exhibited
little binding (Figures 4A and 4B). Moreover, binding of LN1 to
tissues in major organs such as the liver and kidney was much
lower than that observed with the control peptide (Figure 4B).
Colocalization of LN1 with prostate-specific antigen (PSA) anti-140 Molecular Therapy: Oncolytics Vol. 12 March 2019body confirmed that the peptide was bound to tumor cells
(Figure 5).
LNCaP Proliferation Is Inhibited by an LN1-Pro-apoptotic
Peptide Fusion
To ascertain whether homing peptides have potential as vehicles for
targeted drug delivery therapy, we determined whether a fusion
construct composed of the pro-apoptotic peptide D(KLAKLAK)2
and the LN1 peptide could induce death in LNCaP cells. The pro-
apoptotic peptide is known to cause mitochondrial disruption and
induce apoptotic cell death. No change in cell morphology was
observed following treatment with control-KLA peptide or KLA pep-
tide, but significant cell death was induced by the LN1-KLA peptide
(Figure 6A). Proliferation was inhibited by 25 mM LN1-KLA peptide
but not by the same concentration of control-KLA peptide or KLA
peptide (Figure 6B).
LN1-Apoptosis Fusion Peptide Inhibits the Growth of Prostate
Cancer Xenografts
Following in vivo administration of phosphate-buffered saline (PBS),
KLA-peptide, or control-KLA, the tumors displayed heterogeneity in
ultrasound imaging (Figure 7A), indicating that viability was not
affected. On the other hand, the LN1-KLA peptide induced tumor ho-
mogeneity, which was indicative of apoptosis or necrosis (Figure 7A).
Whereas the tumors in control-treated mice grew 2-fold over the
22-day period, growth was reduced to 1.4-fold in mice treated with
LN1-KLA peptide (Figure 7B).
DISCUSSION
In this study, we used phage display technology to identify a homing
peptide that targets human LNCaP xenografts. The LNCaP cell line
isolated from a lymph node metastasis from a prostate cancer pa-
tient.24,25 It expresses relevant markers of prostate cancer cells, such
as PSA, prostate-specific membrane antigen, androgen receptor,
and prostatic acid phosphatase.24,25 Indeed, our primary motivation
for using this cell line was to provide proof of principle that earlier
stages of metastatic prostate cancer could be treated by using homing
peptides.
In vitro and in vivo phage displays have previously identified specific
peptides that selectively bind to prostate cancer cell lines.26,27 Howev-
er, peptides identified using in vitro phage display may not actually
reach tumor cells in an in vivo context. To overcome this issue, we
decided to perform in vivo phage displays and isolate sequence that
were present in the blood, since by definition these represent peptides
that can pass through the general circulation.
In 2006, Newton et al.22 identified peptides that bound selectively to
prostate cancer cells, using in vivo phage display. Although the pep-
tide bound to the prostate cancer tissue, it was also present at signif-
icant levels in the liver. Similarly, in 2011, Askoxylakis et al.,23 using
in vivo phage display, identified peptides that selectively bound to
PC3 cells and suggested that such peptides conjugated with 125I could
be exploited for radiological diagnosis of prostate cancer. However,
Figure 2. Binding of Homing Peptides to LNCaP
Prostate Cancer Cells
(A) LN1, LN2, and LN3 peptides modified with a biotin
molecule were incubated with LNCaP cells for 24 h at a
concentration of 1 mg/mL and the binding affinities of the
respective peptides were compared using fluorescence
with Avidin D-conjugated TRITC (biotinylated peptides are
stained red). Scale bars, 100 mm. (B) The percentage of
TRITC-positive LNCaP cells bound with prostate cancer
homing peptides (n = 6 per group). (C) Comparison of
fluorescence intensity of each target peptide bound to
LNCaP cells (n = 6 per group). Error bars, SD. **p < 0.01.
www.moleculartherapy.orgthe radiolabeled homing peptide bound more avidly to kidney tissue
than to prostate cancer tissue. Thus, promiscuous binding to other
major organs such as the liver and kidney remains a serious limitation
for such peptides. On the other hand, in 2002, Arap et al.12 performed
an in vivo phage display in humans and identified a peptide with high
binding affinity for human prostate tissue. A therapeutic construct of
this peptide fused to a pro-apoptotic peptide was then administered to
patients with advanced human prostate cancer. Although a certain
therapeutic benefit was achieved, dose-limiting toxicity due to rela-
tively high-grade renal dysfunction is a serious issue.28 Identifying
peptides that do not bind to non-diseased tissues is therefore para-
mount. In order to avoid the ethical concerns associated with phage
display in humans, we conducted part of our study in a cynomolgusMolecularmonkey as a surrogate primate species. This
approach identified peptides that do not bind
to liver or kidney tissue and paves the way for
investigation of novel strategies for screening
effective homing peptides. We further validated
our approach by showing that the homing pep-
tides can be used to specifically target death-
inducing pro-apoptotic peptides to tumor cells
in vitro and in vivo.
In order to confirm the application of the iden-
tified peptide for the treatment, an experiment
was conducted in which it was conjugated
with a proapoptotic peptide (D[KLAKLAK]2)
and administered to tumor cells and tumor-
bearing mice for treatment in this study. It
binds to cell surface and causes cell death by dis-
rupting mitochondrial cell membranes.29 It has
been reported that a concentration of approxi-
mately 300 mM is required to induce cell death,
accompanied by morphological change of cells
in eukaryotes when proapoptotic peptide is
administrated alone.19 Here, we observed cell
death accompanied by a morphological change
by inducing LN1-KLA peptide to prostate can-
cer cells and found that the LN1 peptide can
efficiently transport apoptosis-inducing peptide
to prostate cancer cells. Furthermore, LN1-KLApeptide significantly inhibited tumor growth, both in vitro and in vivo,
as compared to the control peptide, and it was considered to be very
useful as a carrier for therapy.
We conclude that the LN1 peptide is a selective and safe carrier for
various therapeutic agents and that our homing peptides screening
strategy will be very useful for identifying specific carriers that can
be used for drug delivery to treat multiple diseases.
MATERIALS AND METHODS
Animals
C57BL/6 mice and severe combined immunodeficient male CB17/Icr-
Prkdcscid/CrlCrlj (C.B-17 SCID) mice were purchased from CharlesTherapy: Oncolytics Vol. 12 March 2019 141
Figure 3. Histological Analysis of Homing Peptide
Binding to Tumor, Liver, and Kidney Tissues in SCID
Mice Bearing LNCaP Cell Xenografts
Tumor, liver, and kidney tissues were excised after each
tumor-targeting peptide was administered to the tumor-
implanted mouse, and DAB staining was performed.
Control peptide was detected in tumor tissue and also in
liver and kidney tissue. Binding of LN3 peptide was
observed in tumor and kidney tissues. In contrast, LN1
and LN2 peptides were found in tumor tissue only. Ar-
rowheads show positive staining of DAB. Scale bars,
100 mm.
Molecular Therapy: OncolyticsRiver Laboratories (Osaka, Japan). The cynomolgus monkey was a gift
from the Research Center for Animal Life Science in Shiga University
of Medical Science.
C.B-17 SCID mice were used for all xenograft experiments with the
human prostate cancer cell line. All mice were housed under standard
conditions in the Institutional Animal Care and Use Committee
(IACUC) at Shiga University of Medical Science and food and water
were provided ad libitum. All animal experiments were conducted
according to the guidelines of the IACUC at Shiga University of Med-
ical Science.
Cell Culture
The human prostate cancer cell line LNCaP (RCB2144) was provided
by the RIKEN BioResource Research Center (BRC) through the
National BioResource Project of the Ministry of Ministry of Educa-
tion, Culture, Sports, Science and Technology/Japan Agency forMed-
ical Research and Development (MEXT/AMED) (Ibaraki, Japan) and
cultured in RPMI-1640 medium (Thermo Fisher Scientific, Waltham,
MA, USA) with 10% fetal bovine serum (Thermo Fisher Scientific) at
37C in an incubator with 5% CO2 and 95% air.
LNCaP Xenograft Model in C.B-17 SCID Mice
Culture medium (250 mL) containing 2  106 LNCaP cells were
mixed with 250 mL Matrigel (Corning, Corning, NY, USA). In order
to generate prostate cancer xenografts, we injected the mixture subcu-
taneously into the back of 6- to 8-week-old C.B-17 SCIDmice, using a
25-gauge needle. Mice were monitored weekly to monitor tumor
growth.
In Vivo Phage Display and Screening of Prostate Cancer Cell
Homing peptides
The M13 phage library (Ph.D.-C7C) was purchased from New En-
gland Biolabs (Ipswich, MA, USA) and was used for in vivo phage
display to screen prostate cancer cell homing peptides. The method
of phage display was performed according to the protocols described142 Molecular Therapy: Oncolytics Vol. 12 March 2019by Christianson et al.,30 with minor modifica-
tions. The phage library was injected into
C57BL/6 mice through the tail vein at a titer
of 1  109 plaque-forming units (PFU)/mL in
100 mL Tris-buffered saline (50 mM Tris-HCl[pH7.5]). Five minutes after the injection, blood was recovered
from the heart in order to remove non-specifically bound phages.
The collected blood was dissolved in DMEM (Thermo Fisher Scien-
tific) containing protease inhibitor (Sigma-Aldrich, St Louis, MO,
USA). The solution was introduced into Escherichia coli ER2738
(New England Biolabs), and the number of phages in the blood was
titrated by plaque-forming units. After amplification to 1  1011
PFU, the phages were injected into new C57BL/6 mice. After three
rounds of in vivo panning with mice, the phages were injected into
the femoral vein of a 15-year-old female cynomolgus monkey. Five
minutes after the injection, blood was taken from the femoral vein
and dissolved in DMEM with protease inhibitor. The solution was
centrifuged to collect the serum, from which phages were amplified
to 1  1011 PFU.
These phages were injected into the tail vein of a C.B-17 SCID mouse
with tumor xenografts, and xenografted prostate cancer tissue was iso-
lated after trans-cardiac removal of blood. Phages were recovered from
the homogenized tissue and amplified as described above. Three addi-
tional cycles of in vivo phage panning were performed. After four cy-
cles of in vivo panning in C.B-17 SCID mice, phage DNA was isolated
from selected phage plaques with high affinity to prostate cancer tis-
sue. The DNA sequence encoding the pIII protein was analyzed in or-
der to identify homing peptides that localize to prostate cancer tissue.
Evaluation of Homing Peptide Binding Affinity to LNCaP Cells
In Vitro and In Vivo
LN1 (C-TGTPARQ-C), LN2 (C-KNSMFAT-C), and LN3
(C-TNKHSPK-C) peptides were synthesized andmodified by a biotin
molecule attached to their N termini (Invitrogen, Carlsbad, CA,
USA). Control peptide (C-GPRTQTA-C), containing a scrambled
version of the amino acid sequence of the LN1 peptide, was synthe-
sized as a control.
For in vitro experiments, LNCaP cells (5  104 cells per well) were
cultured in 24-well plates for 24 h in DMEM with 10% fetal bovine
Figure 4. Quantitative Histological Analysis of LN1
Homing Peptide in Tumor Tissue
(A) The distribution of prostate cancer-specific peptide
(LN1) labeled with TRITC (red) to tumor, liver, or kidney
tissues 5 min after administration of LN1 peptide at a
concentration of 150 mg in 100 mL PBS to tumor-bearing
mice. DAPI staining of nuclei is blue. Scale bars, 50 mm.
(B) Comparison of the fluorescence intensity of LN1
peptide between each tissue (n = 3 per group). Error bars,
SD. **p < 0.01.
www.moleculartherapy.orgserum. Each biotinylated peptide was added to LNCaP cells at
a concentration of 1 mg/mL in 200 mL culture medium. After
incubating LNCaP cells with these peptides at 37C for 5min, the cells
were washed with PBS, to remove the unbound biotinylated peptides,
and fixed with 4% paraformaldehyde. Then each sample was blocked
with PBS containing 5% normal goat serum and incubated withMolecularRhodamine Avidin D (Vector Laboratories,
Burlingame, CA, USA) to visualize the bio-
tinylated peptide. TRITC-positive cells were
observed using a confocal laser microscope
(FV1000-D; Olympus, Tokyo, Japan) with
FLUOVIEW software version 4.01 (Olympus)
and counted in each well; averages were for
each peptide group. Fluorescence intensity was
measured and quantified by ImageJ 1.51
(NIH, Bethesda, MD, USA). These experiments
were performed in triplicate.
For in vivo experiments, 150 mg LN1, LN2, or
LN3 peptide or control peptide was dissolved
into 100 mL PBS and administered through
the tail vein to individual tumor-bearing
mice under general anesthesia. Five minutes
after the administration, xenografted prostate
cancer tissue, liver, and kidney were isolatedafter transcardial perfusion fixation with 4% paraformaldehyde.
Sections prepared from liver, kidney, and tumor tissues were pro-
cessed via DAB (Vector Labs, CA, USA) staining in order to eval-
uate the binding affinity of biotinylated peptides to these tissues
in vivo. For fluorescent staining, the sections of prostate cancer tis-
sue from LN1 and control groups were incubated with anti-PSAFigure 5. Immunohistochemistry of LN1Peptide and
PSA in Tumor Tissue
Analysis of LN1 peptide distribution in tumor tissue by
staining control or LN1 peptide conjugated with biotin.
Staining with TRITC (red) and anti-PSA antibody (green);
the latter is a specific marker of prostate cancer cells.
DAPI staining of nuclei is blue. Scale bars, 50 mm.
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Figure 6. Apoptotic Effects of LN1-KLA Fusion
Peptide in LNCaP Cells
(A) LNCaP cells were incubated with LN1-KLA peptide,
KLA peptide, and control peptide for 48 h at different
concentrations. Cell morphology was observed with an
inverted microscope. Arrowheads show apoptotic cells.
(B) Cell viability was analyzed by WST-8 assay (n = 7 per
group). This ratio was compared with tumor growth in the
PBS-treated group. Error bars, SD. **p < 0.01.
Molecular Therapy: Oncolyticsprimary antibody (GeneTex, Irvine, CA, USA) overnight at 4C.
After the primary antibody was washed out, those sections were
incubated with species-matched AlexaFluor-488 conjugated sec-
ondary antibody (Thermo Fisher Scientific) and Rhodamine
Avidin D. Sections of liver and kidney tissues from the LN1 and
control groups were also incubated with Rhodamine Avidin D.
All sections were observed using a confocal laser microscope
(C1si; Nikon, Tokyo, Japan), with EZC1 software version 3.90
(Nikon). Fluorescence intensity was measured and quantified by
ImageJ 1.51 (NIH, Bethesda, MD, USA). In vivo experiments
were conducted using three mice in each peptide group.
Cell Viability Assay
C-TGTPARQ-C (LN1)-GGG-D(KLAKLAK)2 (LN1-KLA peptide),
C-GPRTQTA-C (control peptide)-GGG-D(KLAKLAK)2 (control-
KLA peptide), and D(KLAKLAK)2 (KLA peptide) were synthesized
by Invitrogen (Carlsbad, CA, USA). LN1 or control peptide and pro-
apoptotic peptide (D[KLAKLAK]2) were linked by a glycinyl-gly-
cinyl-glycine bridge. Therefore, homing peptide (LN1 or control)
and D(KLAKLAK)2 domains could independently move around the
glycine bridge, because the glycine residue has no polarity. LNCaP
cells were seeded in 96-well plates at a density of 1  104 cells per
well and cultured in RPMI-1640 medium with 10% fetal bovine
serum 24 h before the assay. The cells were incubated with different
concentrations of the LN1-KLA fusion peptide, the control-KLA
fusion peptide, or the KLA peptides for 48 h. Cell viability was
measured using the WST8 assay (Dojindo, Kumamoto, Japan).144 Molecular Therapy: Oncolytics Vol. 12 March 2019Treatment of Tumor-Bearing Mice with
Homing Peptides
Immunodeficient mice injected under the dor-
sal skin with LNCaP cells were observed for
approximately 2 months until tumor volume
reached about 150 mm3. Then, LN1-KLA pep-
tide, control-KLA peptide, and KLA peptide
were administered via the tail vein to individual
mice at a concentration of 150 mg dissolved in
100 mL PBS once every 2 days for 3 weeks.
Body weight and tumor size were measured
periodically during the 3 weeks, and the tumor
volume was measured using the Vevo 2100
(Visualsonics, Toronto, Canada), a small-ani-
mal imaging analysis system. This experimentwas performed with six mice in each peptide group, and tumor sizes
were compared between each peptide group.
Statistical Analysis
All in vitro experiments were performed in triplicate. In vivo ana-
lyses were performed in three to six mice per group, with the exact
number shown in the figure legends. Data are expressed as the
mean ± standard deviation (SD). Student’s t tests were performed
to determine the significant differences between two groups. For
multiple datasets, the differences were determined by one-way
ANOVA followed by the Tukey’s test. p < 0.05 was considered sta-
tistically significant.
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